Table 1.
Macrophage phenotypes and their relation to clinical prognosis in osteosarcoma.
| Species | Detection Methods | Markers of Phenotypes | Different Phenotypes of Infiltrating Macrophages | Prognosis Impact | Ref. |
|---|---|---|---|---|---|
| Human | Microarray and IHC analysis | Pan-marker: CD14; M1: HLA-DRα; M2: CD163 | Higher CD14 expression in the non-metastasis group | Higher CD14+ macrophages correlated with metastasis suppression and better OS while M1or M2 not significant | (43) |
| Human | CIBERSORT algorithm | Not mentioned | M0 (0.23 ± 0.1) and M2 (0.24 ± 0.13) fraction of infiltrating immune cells | Higher M1 and M2 macrophages with better OS | (34) |
| Human | CIBERSORT algorithm | Not mentioned | Not mentioned | Higher M0 and lower M2 macrophages with better prognosis | (44) |
| Human | IHC analysis | M2:CD163; Pan-marker: CD68 | High CD163 staining rate (43.8%) and high CD68 staining rate (23.4%) | Higher CD163 macrophages with better OS and MPFS | (45) |
| Human | IHC analysis | Pan-marker: CD68; M1: iNOS | Higher INOS+ macrophages in primary tumor tissues of patients of non-metastasis group | Higher CD68+ macrophages with Better OS | (40) |
| Human | IHC analysis | Pan-marker: CD68 | Not mentioned | Higher CD68+ macrophage with poorer five year-EFS | (46) |
| Human | IHC analysis | Pan-marker: CD68; M2:CCL18 | Higher CD68 in lung metastasis than primary osteosarcoma tissues | Higher CCL18+CD68+ macrophages with poorer prognosis | (47) |
| Human | IHC analysis | Pan-marker: CD14, CD68 | ratio of CD14+/CD68+ TAMs relative to CD45+ cell (6–25%) | Not mentioned | (33) |
| Human | IHC analysis | M2: CD209 | CD209 positive staining rate (78.57%) | Not mentioned | (35) |
| Expression analysis of GEO data | M2: CD163, MRC1 and CCR2 | higher gene expression levels of CD163, MRC1 and CCR2 in tumor | Not mentioned | ||
| Human | IHC, PCR and WB analysis | M2: CD206, Arg-1 and Ym-1 | Upregulation of CD206, Arg-1 and Ym-1 in osteosarcoma tissue than adjacent non-tumor tissue | Not mentioned | (37) |
| Human | FACS analysis | Pan-marker: CD14; M2:CD163 | Higher CD14+/CD163+ macrophages in tumors than peripheral blood | Not mentioned | (38) |
| Human | IHC analysis | Pan-marker: CD68; M1: iNOS; M2: CD163 | Higher CD68+ macrophages in primary tumor tissues of patients with metastasis | Not mentioned | (39) |
| Higher CD68, lower iNOS and unchanged CD163 in metastasis than corresponding primary osteosarcoma tissues | Not mentioned | ||||
| NOD/SCID mice | FACS analysis | Pan-marker: F4/80; M2: CD163 | Upregulation of CD163+/F4/80+ in 3 weeks after tumor implantation | Not mentioned | (41) |
| BALB/c nude mice | IHC analysis | Pan-marker: F4/80 | Higher F4/80+ cells in lung metastases than corresponding primary osteosarcoma tissues | Not mentioned | (39) |
| BALB/c mice | FACS analysis | M1: MHC-II; M2: CD206 | Higher CD206+/MHC-II− macrophages and unchanged CD206−/MHC-II+ in metastatic mouse lung tissue than control lung tissue | Not mentioned | (42) |
IHC, Immunohistochemistry; FACS, Fluorescence-activated Cell Sorting; WB, Western Blot; PCR, Polymerase Chain Reaction; TARGET, Therapeutically Applicable Research to Generate Effective Treatments; GEO, Gene Expression Omnibus.